Nilotinib and imatinib: potential candidates for treatment of dementia and Parkinson's disease through national health insurance data.

ABSTRACT:

Background

Real-world evidence on the potential of tyrosine kinase inhibitors (TKIs) for dementia and Parkinson's Disease (PD) is crucial. This observational study aimed to evaluate TKIs, particularly nilotinib and imatinib, as potential therapeutic agents for these conditions.

Methods

In this retrospective cohort study, 5,579 cancer patients who were prescribed TKIs (users; ≥ 40 years) within 5 years were used, while propensity score-matched patients without any record of TKIs (never users) served as the reference. An association of TKIs with dementia and PD was assessed by the Fine-Gray Model with adjusted-competitive hazard ratios (aCHRs) and 95% confidence intervals (CIs): [aCHRs (95% CIs; p-value)].

Results

The risk of dementia decreased when all types of

SUBMITTER: Song J 

PROVIDER: S-EPMC12420838 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature